Inclusion Criteria

        Each prospective participant must meet ALL of the following inclusion criteria in order to
        be eligible for this study:

          -  Signed written informed consent granted prior to initiation of any study-specific
             procedures

          -  For the dose escalation cohorts, relapsed or refractory (R/R) participants with a
             diagnosis of B-cell Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL)/
             small lymphocytic lymphoma (SLL) and Waldenstrom macroglobulinemia (WM) who have
             received at least two prior systemic therapies . Participants must have failed or are
             intolerant to standard therapies and cannot be a candidate for standard salvage
             regimens. Participants with low grade lymphoma must be progressing and requiring
             treatment

          -  For the expansion cohorts, the following criteria must be met:

               -  Cohort A: R/R CLL/SLL participants with at least 2 prior systemic therapies and
                  previously treated with a covalent Bruton's tyrosine kinase inhibitor (BTKi) who
                  must have a documented Bruton's tyrosine kinase (BTK) mutation on C481 residue

               -  Cohort B: R/R CLL/SLL participants who have failed or were intolerant to a BTKi
                  with documentation of the absence of BTK mutation on C481 residue. In this study,
                  intolerance to standard therapy is defined as having experienced a grade 3 or
                  higher adverse event that was caused by the standard therapy and resulted in
                  treatment discontinuation

               -  Cohort C: Richter's transformation (RT) participants who have failed at least one
                  prior therapy

               -  Cohort D: Follicular Lymphoma (FL) participants who have failed at least 2 prior
                  systemic therapies and are histology grade 1, 2, or 3A

               -  Cohort E: Mantle Cell Lymphoma (MCL) participants who have failed at least 2
                  prior systemic therapies

               -  Cohort F: Marginal Zone Lymphoma (MZL) participants who have failed at least 2
                  prior systemic therapies

               -  Cohort G: High-grade B-cell lymphoma participants who have failed at least 2
                  prior systemic therapies and have known MYC and BCL2 and/or BCL6 translocations

               -  Cohort H: WM participants who have failed at least 2 prior systemic therapies

          -  Disease status requirement:

               -  For CLL participanst symptomatic disease that mandates treatment (Hallek et al.
                  2018)

               -  For B-cell NHL participants, measurable disease by imaging scan

               -  For WM, serum immunoglobulin M (IgM) with a minimum IgM level of ≥ 2 times the
                  upper limit of normal (ULN)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Good organ function

          -  Creatinine clearance of ≥ 60 mL/min as estimated by the Cockcroft-Gault equation or by
             24-hour urine collection

          -  Total bilirubin ≤ 1.5 x institutional ULN (total bilirubin of ≤ 3 x institutional ULN
             in participants with documented Gilbert's syndrome)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ×
             institutional ULN

          -  Platelet count ≥ 50,000/µL

          -  Absolute neutrophil count (ANC) ≥ 1000/µL

          -  Hemoglobin (Hgb) ≥ 8.0 g/dL, stable for ≥ 1 week.

          -  For men and women of child-bearing potential, willing to use adequate contraception
             (e.g., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire
             duration of the study

          -  Female participants of child-bearing potential must have a negative serum pregnancy
             test within 14 days of the first day of drug dosing

          -  Ability to swallow oral medications without difficulty

        Exclusion Criteria

        Potential participants who meet ANY of the following exclusion criteria are not eligible
        for enrollment into this study:

          -  Had immunotherapy, radiotherapy, radioimmunotherapy, biological therapy, chemotherapy,
             or treatment with an investigational product within 5 half-lives or four weeks
             (whichever is shorter) prior to treatment initiation, or oral therapy within 5
             half-lives or one week (whichever is shorter) prior to treatment initiation

          -  Transformation of follicular lymphoma (FL) to a more aggressive subtype of lymphoma or
             grade 3b FL

          -  Participants currently being treated with the following drugs:

               -  cytochrome P 450 (CYP) 2C9 substrates with a narrow therapeutic index (such as
                  warfarin, phenytoin)

               -  CYP 2C8 substrates with a narrow therapeutic index (such as paclitaxel)

               -  CYP 2C19 substrates with a narrow therapeutic index (such as S-mephenytoin)

               -  CYP 2D6 substrates with a narrow therapeutic index (such as thioridazine,
                  pimozide)

               -  P-gp substrates with a narrow therapeutic index (such as digoxin) Note: A washout
                  period of at least 5 times the half-life after the last dose of any of the above
                  treatments is required for a participant to be eligible for study enrollment

          -  Prior allogeneic bone marrow transplant

          -  Active central nervous system (CNS) involvement

          -  Pregnant or breast-feeding women

          -  Has significant, ongoing co-morbid conditions which would preclude safe delivery of
             the study drug

          -  Uncontrolled illness including but not limited to ongoing or active infection,
             symptomatic congestive heart failure (New York Heart Association [NYHA] Class III or
             IV heart failure), unstable angina pectoris, cardiac arrhythmia, cardiac infarction in
             the past six months, and psychiatric illness that would limit compliance with study
             requirements

          -  QT corrected (QTc) prolongation (defined as a QTc > 450 msecs) or other significant
             electrocardiogram (ECG) abnormalities including 2nd degree atrioventricular (AV) block
             type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50
             beats/min). If the screening ECG has a QTc > 450 msecs, the ECG can be submitted for a
             centralized, cardiologic evaluation.

          -  Active human immunodeficiency virus (HIV) infection, Hepatitis B, or Hepatitis C
             infection.

          -  Other medical or psychiatric illness or organ dysfunction which, in the opinion of the
             Investigator, would either compromise the participant's safety or interfere with the
             evaluation of the safety of the study agent

          -  History of prior cancer within < 1 year, except for basal cell or squamous cell
             carcinoma of the skin, cervical cancer in situ or other in situ carcinomas